InvestorsHub Logo
Followers 237
Posts 10817
Boards Moderated 0
Alias Born 07/17/2006

Re: None

Wednesday, 04/16/2014 5:27:07 PM

Wednesday, April 16, 2014 5:27:07 PM

Post# of 424560
Crazy prices.

Recent sell off is a prime example of the mindless nature of Wall Street. Since the FDA's "Red Wedding" last October the game has been all about REDUCE-IT. Lovaza has and never will be a threat to the real value of V. Lovaza has not even been able to capture the full exent of the >500mg trig market. It has none of the qualities that make V potentially so valuable, never has and never will have..Hope you used yesterday to buy some V at bargain prices.

The biggest threat to V, is V itself. If it works the way the science says it does and moderates chronic inflammation then you are getting the bargain of a lifetime..If REDUCE_IT fails then you are out the buck sixty a share..Its all about implied odds. The market loves this kiind of bet, but it does not understand pathophysiology. The science looks very good and the fact the FDA is deliberately ignoring the science does not mean the science has gone away.

In reality JELIS tells us EPA works, not because of the comparison of the results of the treated group with the placebo. The import comparison is the much better heart health in the entire JELIS Japanese cohort with a comparitive group of Americans adjusted for age and sex..Less than 100 patients died out of 18,000 over a 5 year period...Japanese have significantly higher EPA/AA ratios.. Do you think a similar group of Americans would have only had 100 deaths?

":>) JL

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News